Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Ramucirumab

EU orphan designation number: EU/3/12/1019   
Active ingredient: Ramucirumab
Indication: Treatment of hepatocellular carcinoma
Sponsor: Eli Lilly Nederland B.V.
Grootslag 1-5, NL-3991 RA Houten, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
06/07/2012 Orphan Designation EMA/OD/031/12 (2012)4773 of 04/07/2012